Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab Dosing Strategies for PED in Neovascular AMD (DETAIL)
NCT00590694Phase 3Completed
- Sponsor
- Pacific Eye Associates
- Start
- Oct 2006
- Primary completion
- Dec 2009
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ranibizumab in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by Pacific Eye Associates. Primary endpoint: Mean change in visual acuity from baseline at 12 months. Started Oct 2006; status: completed.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00590694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00590694.